BPH Global shares surged today, as much as 50% to A$0.003, positioning for the best day since Aug 11, given the gains sustain.

The biotech company announced it would fully acquire Foshan Gedishi Biotechnology, an operator of the birds' nest pilot study in partnership with BPH’s associates in China.

This deal is anticipated to resurrect and expand BPH’s bird nest enterprise in China, with the transaction expected to close by Oct 31.

The company’s stock has reached its apex level since Aug 15, despite a descent of 84.8% YTD.

BPH Global (ASX:BP8) is a biotechnology company that aims to develop and enhance the scope of their birds' nest business in China.